Exelon (Rivastigmine Tartrate) - Summary

EXELON SUMMARY

Exelon

Exelon® (rivastigmine tartrate) is a reversible cholinesterase inhibitor.

Exelon® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

EXELON NEWS HIGHLIGHTS

Media Articles Related to Exelon (Rivastigmine)

Antihypertensive Treatment On Cognitive Functions In Alzheimer's Disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2008.09.03]

Alzheimer's Disease: Home Safety Information
Source: MedicineNet Advance Medical Directives Specialty [2008.08.26]

Alzheimer's Disease Patient Caregiver Guide
Source: MedicineNet Dehydration Specialty [2008.08.26]

Initiatives Seek To Reduce Salt Intake Among Blacks, Offer Health Benefits Assistance To Hispanics, Examine Caring For People With Alzheimer's Disease
Source: Hypertension News From Medical News Today [2008.08.18]

Physical Frailty Could Predict Alzheimer's Disease
Source: MedicineNet Dementia Specialty [2008.08.14]

more>>

Published Studies Related to Exelon (Rivastigmine)

Rivastigmine in Parkinson's disease dementia. [2008.08]

Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia : a retrospective analysis of a double-blind trial and an open-label extension. [2008]

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2008]

Rivastigmine exposure provided by a transdermal patch versus capsules. [2007.12]

Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. [2007.10]

more>>

Clinical Trials Related to Exelon (Rivastigmine)

Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease [Completed]

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients [Terminated]

Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment [Completed]

A Double-Blind, Placebo-Controlled Crossover Study of Repeat Rivastigmine (Exelon®) Administration in Young Healthy Male Volunteers [Not yet recruiting]

Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment [Completed]

more>>